Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells. The role of BCL-2

Biochemical Pharmacology

Volumn 55, Issue 3, 1998, Pages 349-359

  Reber, Ulrike ^a   Wüllner, Ulrich ^a   Trepel, Martin ^a   Baumgart, Jürgen ^b   Seyfried, Jan ^a   Klockgether, Thomas ^a   Dichgans, Johannes ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MEDAC GMBH   (Germany)

Author keywords

Apoptosis; BSO; Chemotherapy; Glutathione; Malignant glioma; Treosulfan

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BUTHIONINE SULFOXIMINE; CYTARABINE; DOXORUBICIN; GLUTATHIONE; NIMUSTINE; PROTEIN P53; TENIPOSIDE; TREOSULFAN; VINCRISTINE;

ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 17744402925     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00480-2     Document Type: Article

References (39)

1. Weller M, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma prevention of efficacy by dexamethasone? Neurology. 48:1997;1704-1709.
2. Weller M, Malipiero UV, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 95:1995;2633-2643.
3. Roth W, Fontana A, Trepel M, Dichgans J, Reed JC, Weller M. Immunochemotherapy of malignant glioma synergistic activity of CD95 ligand and chemotherapeutics . Cancer Immunol Immunother. 44:1997;55-63.
4. Weller M. Genetic regulation and therapeutic modulation of apoptosis in human malignant glioma. Cell Physiol Biochem. 6:1996;376-380.
5. Ali-Osman F, Stein DE, Renwick A. Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. Cancer Res. 50:1990;6976-6980.
6. Black SM, Wolf CR. The role of glutathione-dependent enzymes in drug resistance. Pharmac Ther. 51:1991;139-154.
7. Grant R, Ironside JW. Glutathione S-transferases and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma. J Neuro-Oncol. 25:1995;1-7.
8. Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E. Buthionine sulfoximine induction of γ-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells. Mol Pharmacol. 49:1996;1012-1020.
9. Matsumoto Y, Fujiwara T, Nagao S. Determinants of drug response in camptothecin-11-resistant glioma cell lines. J Neuro-Oncol. 23:1995;1-8.
10. Allalunis-Turner MJ, Day RS, McKean JDS, Petruk KC, Allen PBR, Aronyk KE, Weir BKA, Huyser-Wierenga D, Fulton DS, Urtasun RC. Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. J Neuro-Oncol. 11:1991;157-164.
11. Lippitz BE, Halperin EC, Griffith OW, Colvin OM, Honore G, Ostertag CB, Bigner DD, Friedman HS. L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice. Neurosurgery. 26:1990;255-260.
12. Saito Y, Nakada Y, Hotta T, Mikami T, Kurisu K, Yamada K, Kiya K, Kawamoto K, Uozumi T. Glutathione and cellular response of ACNU-resistant rat glioma sublines to drugs and radiation. Int J Cancer. 48:1991;861-865.
13. Van Meir KG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJS, Friedmann T, De Tribolet N, Cavenee WK. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54:1994;649-652.
14. Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S, Reed JC. Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. Neurol Res. 19:1997;459-470.
15. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells Induction and modulation of sensitivity by cytokines . J Clin Invest. 94:1994;954-964.
16. Weller M, Malipiero U, Rensing-Ehl A, Barr P, Fontana A. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55:1995;2934-2944.
17. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear fragmentation. J Cell Biol. 119:1992;493-501.
18. + toxicity in nigral dopaminergic neurons. Neuroreport. 7:1996;921-923.
19. Meredith MJ, Reed DJ. Status of the mitochondrial pool of glutathione in the isolated hepatocyte. J Biol Chem. 257:1982;3747-3753.
20. Schulz JB, Weller M, Klockgether T. Potassium deprivation-induced apoptosis of cerebellar granule neurons a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species . J Neurosci. 16:1996;4696-4706.
21. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Örd T, Bredesen DE. Bcl-2 inhibition of neural death decreased generation of reactive oxygen species . Science. 262:1993;1274-1277.
22. Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G, Kane DJ, Testa MP, Kayalar C, Bredesen DE. Shift of the cellular oxidation-reduction potential in neural cells expressing bcl-2. J Neurochem. 67:1996;1259-1267.
23. Feit PW, Rastrup-Andersen N, Matagne R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate . J Med Chem. 13:1970;1173-1175.
24. Wilson AP, Neal FE. In vitro sensitivity of human ovarian tumors to chemotherapeutic agents. Br J Cancer. 44:1981;189-200.
25. Köpf-Maier P, Sass G. Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol. 37:1996;211-221.
26. Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S, Niitsu Y. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 56:1996;3577-3582.
27. Hockenbery D, Oltvai Z, Yin XM, Milliman C, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 75:1993;241-248.
28. Steinman HM. The bcl-2 oncoprotein functions as a pro-oxidant. J Biol Chem. 270:1995;3487-3490.
29. Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biol Sci. 21:1996;83-86.
30. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by bcl-2 release of cytochrome c from mitochondria blocked . Science. 275:1997;1129-1132.
31. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria a primary site for bcl-2 regulation of apoptosis . Science. 275:1997;1132-1136.
32. Hedley DW, McCulloch EA. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside role of bcl-2 . Leukemia. 10:1996;1143-1149.
33. Kang YJ, Enger MD. Buthionine sulfoximine-induced cytostasis does not correlate with glutathione depletion. Am J Physiol. 262:1992;C122-C127.
34. Hilger RA, Harstrick A, Skorzec M, Baumgart J and Scheulen ME, Clinical pharmacokinetics of i.v. treosulfan: a new method for the quantification of treosulfan. 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, 1996.
35. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan an attempt at modulation of glutathione . J Clin Oncol. 12:1994;194-205.
36. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol. 14:1996;249-256.
37. Tsutsui K, Komuro C, Ono K, Nishidai T, Shibamoto Y, Takahashi M, Abe M. Chemosensitization by buthionine sulfoximine in vivo. Int J Radiat Oncol Biol Phys. 12:1986;1183-1186.
38. Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC, Hilton J, Bigner DD. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. J Natl Cancer Inst. 81:1989;524-527.
39. Pileblad E and Magnusson T, Intracerebroventricular administration of L-buthionine sulfoximine: a method for depleting glutathione. J Neurochem 53: 1878-1882, 1989.